[Progressive encephalomyelitis with rigidity responsive to gabapentin: a pharmacological update].
J
J
Gazulla Abío
I
I
Benavente Aguilar
J L
JL
Capablo Liesa
D000588:Amines / Q000627:therapeutic use*; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D003000:Clonidine / Q000031:analogs & derivatives*; D003509:Cyclohexanecarboxylic Acids / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D004679:Encephalomyelitis / Q000188:drug therapy* / Q000503:physiopathology; D018755:GABA Agonists / Q000627:therapeutic use; D000077206:Gabapentin; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D009127:Muscle Rigidity / Q000188:drug therapy* / Q000503:physiopathology; D009557:Nipecotic Acids / Q000627:therapeutic use; D000078308:Tiagabine; D005680:gamma-Aminobutyric Acid / Q000627:therapeutic use*
D000588:Amines; D000978:Antiparkinson Agents; D003509:Cyclohexanecarboxylic Acids; D018755:GABA Agonists; D016756:Immunoglobulins, Intravenous; D009557:Nipecotic Acids; D005680:gamma-Aminobutyric Acid; C023754:tizanidine; D000077206:Gabapentin; D003000:Clonidine; D000078308:Tiagabine